(Posted By: Josi Creek)
Biogen
Idec today announced that 38 company-sponsored platform
and poster presentations will be presented during the American
Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto,
April 10 -- 17, 2010. The AAN Annual Meeting is the world's largest
gathering of neurologists. These presentations include data on five
compounds that are marketed or currently in development by
Biogen Idec and its partners for the treatment of multiple
sclerosis (MS), including two approved therapies for MS,
TYSABRI(R) (natalizumab) and AVONEX(R) (interferon
beta-1a), and three promising compounds in the late stages of
development: BG-12 (dimethyl fumarate), PEGylated interferon beta-1a
and daclizumab.